Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8224503 | 1.00 | CNR2 (0.36) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7992568 | 1.00 | CNR2 (0.36) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8002693 | 0.93 | CNR2 (0.34) | CNR2KCNH2GSK3B | |
| SCHEMBL8224975 | 0.93 | CNR2 (0.34) | CNR2KCNH2GSK3B | |
| SCHEMBL13601242 | 0.93 | CNR2 (0.34) | CNR2KCNH2GSK3B | |
| SCHEMBL8227066 | 0.90 | BACE1 (0.34) | CNR2CYP2D6CYP2C19CYP1A2KCNH2 | |
| SCHEMBL8004952 | 0.90 | BACE1 (0.34) | CNR2CYP2D6CYP2C19CYP1A2KCNH2 | |
| SCHEMBL4512185 | 0.90 | CNR2 (0.32) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8219592 | 0.90 | CNR2 (0.32) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4518261 | 0.90 | CNR2 (0.32) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | REN, AGTR1, AGTR2 | CNR2 402/4885CYP3A4 542/4885CYP2D6 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.